Production (Stage)
Coeptis Therapeutics Holdings, Inc.
COEP
$8.23
-$0.13-1.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -56.97% | -6.51% | 39.75% | -1.13% | 20.08% |
| Total Depreciation and Amortization | 17.42% | -6.54% | 11.19% | -3.51% | 1.85% |
| Total Amortization of Deferred Charges | 50.91% | -- | -- | -100.00% | -- |
| Total Other Non-Cash Items | 120.96% | 213.00% | -114.54% | 128.21% | -32.32% |
| Change in Net Operating Assets | -398.42% | 68.08% | -378.62% | -137.32% | -91.40% |
| Cash from Operations | -64.72% | 24.10% | -33.50% | 25.48% | -12.32% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Investing | -- | -- | -- | 100.00% | -- |
| Total Debt Issued | -- | -- | -100.00% | -62.96% | 800.00% |
| Total Debt Repaid | -244.57% | -- | 100.00% | -4.35% | 17.86% |
| Issuance of Common Stock | -- | -- | -- | -- | -71.45% |
| Repurchase of Common Stock | -- | -- | 88.89% | -- | -- |
| Issuance of Preferred Stock | 666.47% | -54.40% | -9.96% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -- | -- |
| Cash from Financing | 733.57% | -50.37% | -24.11% | 24.39% | -10.79% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 717.85% | -44.78% | -179.42% | 219.53% | -863.72% |